Profile data is unavailable for this security.
About the company
Beam Therapeutics Inc. is a biotechnology company developing precision genetic medicines through base editing. The Company's suite of gene editing technologies is anchored by base editing, a technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the deoxyribonucleic acid. Its lead programs are focused on sickle cell disease and alpha-1 antitrypsin deficiency, and it is also advancing programs in other genetic diseases. Its primary programs include BEAM-101, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-302 and BEAM-301. BEAM-101 is a patient-specific, autologous hematopoietic stem cell (HSC), investigational therapy. ESCAPE is a potentially non-genotoxic approach to HSC transplantation. BEAM-302 is a liver-targeting lipid nanoparticle formulation of base editing reagents designed to offer a one-time treatment to correct the E342K point mutation (PiZZ genotype).
- Revenue in USD (TTM)63.58m
- Net income in USD-387.34m
- Incorporated2017
- Employees483.00
- LocationBeam Therapeutics Inc238 Main StreetCAMBRIDGE 02142United StatesUSA
- Phone+1 (857) 327-8775
- Fax+1 (302) 655-5049
- Websitehttps://beamtx.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ARS Pharmaceuticals Inc | 97.12m | -15.65m | 1.58bn | 155.00 | -- | 6.90 | -- | 16.27 | -0.2536 | -0.2536 | 0.9449 | 2.33 | 0.35 | -- | 17.83 | 626,593.60 | -5.64 | -14.27 | -5.98 | -14.82 | 97.35 | -- | -16.11 | -224.85 | 10.74 | -- | 0.00 | -- | 297,063.30 | -- | 114.71 | -- | 42.45 | -- |
| Adaptive Biotechnologies Corp | 189.53m | -141.84m | 1.70bn | 619.00 | -- | 8.93 | -- | 8.97 | -0.9592 | -0.9592 | 1.28 | 1.25 | 0.3351 | 6.46 | 4.43 | 306,182.60 | -25.09 | -21.92 | -29.54 | -24.85 | 62.53 | 64.77 | -74.87 | -119.25 | 2.82 | -- | 0.4125 | -- | 5.10 | 16.04 | 29.19 | -- | -20.03 | -- |
| Beam Therapeutics Inc | 63.58m | -387.34m | 1.76bn | 483.00 | -- | 1.57 | -- | 27.73 | -4.61 | -4.61 | 0.758 | 11.17 | 0.045 | -- | -- | 131,631.50 | -27.41 | -24.98 | -31.01 | -29.69 | -- | -- | -609.24 | -241.53 | -- | -- | 0.00 | -- | -83.18 | 412.30 | -184.28 | -- | -6.50 | -- |
| Disc Medicine Inc | 0.00 | -116.49m | 1.77bn | 84.00 | -- | 2.68 | -- | -- | -3.92 | -3.92 | 0.00 | 19.10 | 0.00 | -- | -- | 0.00 | -21.91 | -- | -22.62 | -- | -- | -- | -- | -- | -- | -- | 0.0414 | -- | -- | -- | -43.08 | -- | -- | -- |
| Grail Inc | 130.71m | -1.91bn | 1.77bn | 1.00k | -- | 0.7199 | -- | 13.55 | -60.98 | -60.98 | 4.00 | 68.38 | 0.0383 | -- | 7.61 | 130,711.00 | -56.13 | -49.71 | -57.94 | -50.85 | 44.26 | 39.69 | -1,464.53 | -3,510.18 | -- | -- | 0.00 | -- | 34.90 | -- | -38.30 | -- | 9.34 | -- |
| Amicus Therapeutics, Inc. | 543.14m | -29.37m | 1.80bn | 499.00 | -- | 9.29 | -- | 3.31 | -0.0961 | -0.0961 | 1.78 | 0.6286 | 0.7186 | 0.5288 | 6.59 | 1,088,459.00 | -3.89 | -23.63 | -4.83 | -28.66 | 90.60 | 89.34 | -5.41 | -53.29 | 2.47 | 1.09 | 0.6687 | -- | 32.29 | 23.72 | 62.99 | -- | -29.23 | -- |
| Ideaya Biosciences Inc | 7.00m | -307.08m | 1.85bn | 131.00 | -- | 1.81 | -- | 264.25 | -3.59 | -3.59 | 0.0824 | 11.70 | 0.0068 | -- | -- | 53,435.11 | -29.78 | -22.71 | -30.92 | -24.48 | -- | -- | -4,386.90 | -411.78 | -- | -- | 0.00 | -- | -70.07 | -- | -142.98 | -- | 23.31 | -- |
| Belite Bio Inc (ADR) | 0.00 | -42.55m | 1.86bn | 25.00 | -- | 11.77 | -- | -- | -1.36 | -1.36 | 0.00 | 4.86 | 0.00 | -- | -- | 0.00 | -32.07 | -- | -32.07 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -14.26 | -- | -- | -- |
| BioCryst Pharmaceuticals Inc | 503.49m | -53.47m | 1.88bn | 580.00 | -- | -- | -- | 3.74 | -0.2583 | -0.2583 | 2.41 | -2.16 | 1.06 | 0.8545 | 6.54 | 868,077.60 | -11.28 | -40.01 | -15.54 | -53.68 | 96.89 | 97.34 | -10.62 | -75.69 | 2.88 | 0.3933 | 2.23 | -- | 36.00 | 55.97 | 60.77 | -- | 26.79 | -- |
| Agios Pharmaceuticals Inc | 37.04m | 665.99m | 1.99bn | 486.00 | 3.05 | 1.36 | 2.96 | 53.75 | 11.29 | 11.29 | 0.6447 | 25.33 | 0.0308 | 0.1755 | 10.90 | 76,203.70 | 55.38 | -10.38 | 57.88 | -11.09 | 87.52 | -- | 1,798.26 | -768.40 | 17.93 | -- | 0.00 | -- | 36.07 | -- | 291.35 | -- | -32.66 | -- |
| CG Oncology Inc | 662.00k | -105.56m | 2.01bn | 113.00 | -- | 2.85 | -- | 3,034.04 | -1.50 | -1.50 | 0.0095 | 9.25 | 0.001 | -- | 2.66 | 5,858.41 | -16.15 | -- | -16.56 | -- | -- | -- | -15,945.17 | -- | -- | -- | 0.00 | -- | 458.33 | -- | -29.85 | -- | -- | -- |
| Denali Therapeutics Inc | 0.00 | -453.94m | 2.03bn | 443.00 | -- | 1.80 | -- | -- | -2.67 | -2.67 | 0.00 | 7.73 | 0.00 | -- | -- | 0.00 | -31.83 | -16.91 | -33.90 | -19.81 | -- | -- | -- | -135.24 | -- | -- | 0.005 | -- | -100.00 | -- | -191.12 | -- | -2.35 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Farallon Capital Management LLCas of 31 Mar 2025 | 9.93m | 9.87% |
| The Vanguard Group, Inc.as of 31 Mar 2025 | 8.70m | 8.65% |
| ARK Investment Management LLCas of 31 Mar 2025 | 8.48m | 8.43% |
| BlackRock Fund Advisorsas of 31 Mar 2025 | 6.76m | 6.72% |
| Fidelity Management & Research Co. LLCas of 31 Mar 2025 | 6.46m | 6.42% |
| Nikko Asset Management Americas, Inc.as of 31 Mar 2025 | 4.27m | 4.25% |
| SSgA Funds Management, Inc.as of 31 Mar 2025 | 3.44m | 3.42% |
| T. Rowe Price Associates, Inc. (IM)as of 31 Mar 2025 | 2.94m | 2.93% |
| Kynam Capital Management LPas of 31 Mar 2025 | 2.52m | 2.50% |
| Bellevue Asset Management AGas of 31 Mar 2025 | 2.40m | 2.38% |
